Literature DB >> 16925792

Fracture risk in patients with monoclonal gammopathy of undetermined significance.

Henrik Gregersen1, Paw Jensen, Mette Gislum, Birgit Jørgensen, Henrik Toft Sørensen, Mette Nørgaard.   

Abstract

Little information is available on the risk of fractures in patients with monoclonal gammopathy of undetermined significance (MGUS). We identified 1535 patients with MGUS between 1978 and 2003 in North Jutland County, Denmark. The population control group consisted of 15 350 persons selected from the Danish Central Population Registry, matched by age and sex. Data on fractures in the two groups were obtained from the regional Hospital Discharge Registry. In the MGUS cohort, 187 first-time fractures were identified during 9754 person-years of follow-up, corresponding to an incidence rate of 19/1000 person-years. The adjusted relative risk for fractures among MGUS patients compared with population controls was 1.4 [95% confidence interval (CI), 1.2-1.6]. After 5 years of follow-up, the risk difference was 1.8% (95% CI, 0.5-3.0). Six of the 187 MGUS patients with fractures were later diagnosed with malignant transformation. Relative risks for fractures were increased in IgG-type MGUS [1.3 (95% CI,1.1-1.6)], IgM-type MGUS [1.6 (95% CI, 1.1-2.2)] and MGUS with kappa light chain [1.4 (95% CI, 1.1-1.7)]. MGUS patients had an increased risk of fractures, which could not be explained by comorbidity, advanced age, gender or malignant transformation.

Entities:  

Mesh:

Year:  2006        PMID: 16925792     DOI: 10.1111/j.1365-2141.2006.06269.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

Review 3.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

Review 4.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

5.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

Review 6.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 7.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 8.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

Review 9.  Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis.

Authors:  Nicola Veronese; Claudio Luchini; Marco Solmi; Giuseppe Sergi; Enzo Manzato; Brendon Stubbs
Journal:  J Bone Miner Metab       Date:  2017-02-27       Impact factor: 2.626

10.  Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.

Authors:  Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.